CapsoVision Inc. (CV)
NASDAQ: CVHealth CareBiotechnology: Electromedical & Electrotherapeutic ApparatusUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CV stock chart
Technical analysisKey statistics
All statistics- Market cap
- $327.56M
- EPS (TTM)
- -$0.42
- Dividend yield
- None
- 52-week range
- 4.50 – 15.37
- Day range
- 6.01 – 6.37
- Volume / Avg
- 178.65K / 173.59K
- Beta
- —
- Shares outstanding
- 53.61M
52-week range
CV stock today
CapsoVision (CV) closed at $6.11 on Nov 20, down 3.17% (-$0.20), versus the S&P 500's 3.70% decline. Shares are 60.2% below their 52-week high of $15.37, set on Dec 11, 2025 and 35.8% above the 52-week low of $4.50, near the bottom of the past year's range. CV is down 42.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 16.8%.
CapsoVision has posted a net loss over the last twelve months (EPS of -$0.42), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About CapsoVision
Company profileCapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). It also provides CapsoCloud cloud-based software-as-a-service ecosystem as an off-premises video access and download solution; CapsoView, a data access reading device for viewing capsule videos; CapsoAccess, a Capsule data access system; and CapsoRetrieve, a retrieval kit to recover the capsule using a magnetic wand, as well as capsule video reading services.
- Sector
- Health Care
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- CEO
- Mr. Kang-Huai Wang
- Headquarters
- Saratoga, CA
- Employees
- 99
- IPO year
- 2025
- Website
- capsovision.com
Financial highlights
Full financialsIn fiscal 2025, CapsoVision generated $13.6 million in revenue, up 15.3% from fiscal 2024. CapsoVision reported a net loss of $25.3 million, compared with a loss of $19.9 million a year earlier. Gross margin was 52.9% (down from 54.2%) and operating margin -188.3%.
| Fiscal year | FY 2025 | FY 2024 |
|---|---|---|
| Revenue | $13.55M | $11.76M |
| Growth | +15.29% | — |
| Net income | $-25.32M | $-19.90M |
| EPS (diluted) | $-1.03 | $-9.85 |
Analyst forecast
ForecastConsensus (2 analysts)
strong_buy
Avg. price target
$9.50+55.48%
- Strong buy 0
- Buy 2
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.15 vs $-0.15
- Surprise
- 0.00%
CV news
All CV news- CapsoVision (CV) Q3 2026 Earnings Call TranscriptNasdaq
- CapsoVision, Inc Q3 Loss DropsNasdaq
- CapsoVision to Release Third Quarter 2026 Financial Results on November 12, 2026GlobeNewswire
- CapsoVision to Present at the 20th Annual LD Micro Main EventGlobeNewswire
- Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report DataNasdaqABBV, AZN, CBLL, CDXS
- After Hours Most Active for Sep 25, 2026 : FTXN, ABUS, FTXH, CMCSA, NVDA, CSCO, JPM, BMNR, EQT, CNP, PFE, CVSNasdaqFTXN, ABUS, FTXH, CMCSA
CapsoVision peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ELMDElectromed Inc. | 22.98 | -1.20% | $187.84M | vs CV |
| FOCLEDAP TMS S.A. ADR | 2.61 | -7.45% | $123.25M | vs CV |
| VANIVivani Medical Inc. | 1.14 | +4.59% | $102.83M | vs CV |
| STXSStereotaxis Inc. | 0.9422 | -6.71% | $95.03M | vs CV |
| HSDTSolana Company Class A | 1.49 | -10.24% | $93.70M | vs CV |
| NRXSNeuraxis Inc. | 4.22 | -6.22% | $59.90M | vs CV |
| HYPRHyperfine Inc. Class A | 0.5465 | +4.27% | $57.96M | vs CV |
| OMOutset Medical Inc. | 2.81 | -3.44% | $53.03M | vs CV |
Indexes, lists and sector
CapsoVision stock FAQ
What is CapsoVision's stock price today?
CV last traded at $6.11 as of Nov 20, 4:00 PM EST, down 3.17% on the day. Prices are delayed at least 15 minutes.
Who is CapsoVision's CEO?
Mr. Kang-Huai Wang is the chief executive officer of CapsoVision Inc., which has about 99 employees.
What is the CV 52-week high?
The 52-week high for CV is $15.37 and the 52-week low is $4.50. The stock is currently 60.2% below its high.